Walgreens Boots Alliance, Inc.(NASDAQ:WBA) reported its Q3 results, with EPS of $0.96 coming in better than the Street estimate of $0.91. Revenue was $32.6 billion, above the Street estimate of $32.01 billion.
The beat was driven by better than forecasted Covid vaccines and tests, a sharp rebound in the International segment, offset by higher than expected losses in the burgeoning Walgreens Health segment.
The company maintained its full 2022-year guidance. However, analyst at Deutsche Bank model core US pharmacy EBITDA ex vaccines to be down 26.5% year-over-year, and the company’s guidance commentary suggests the US EBITDA could be down approximately 25% in Q4, implying a weakened core as the run rate headed into 2023.
At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com